+1 (629)348-3199Symbiotic bacteria provide chemoprevention against hepatitis B virus mediated hepatocellular carcinoma in hepatitis B x transgenic mice
World Liver Conference 2018
May 25-26, 2018 | New York, USA
Mark A Feitelson
Temple University, USA
Keynote : J Gastroenterol Dig Dis
Abstract:
Chronic infection with hepatitis B virus (HBV) is associated with the development of progression of chronic liver disease (CLD) and the appearance of hepatocellular carcinoma (HCC). HCC is a prevalent cancer worldwide with few treatment options. Given that HCC develops most often on the background of chronic inflammation, experiments were designed to test the hypothesis that selected probiotic bacteria that suppress inflammation could be used as a simple and inexpensive means to prevent or delay the appearance of HCC. To test this, hepatitis B x (HBx) transgenic mice, which develop progressive liver lesions that culminate in HCC, were treated with a mixture of probiotic bacteria (Synbiotic 2000) several months prior to the development of dysplasia and HCC. The results showed a significant reduction in the number and size of dysplastic and HCC nodules compared to control transgenic mice. Microarray analysis of selected immune and cancer associated markers showed a strong reduced expression in the liver of mice treated with Synbiotic 2000 compared to controls. Thus, Synbiotic 2000 attenuates the pathogenesis of HCC, and may be useful in cancer chemoprevention, not only for HCC, but perhaps against other cancers that often develop on the background of chronic inflammation.
Biography:
Mark A Feitelson received his PhD in Microbiology and Immunology in 1979 from the UCLA School of Medicine. He was an American Cancer Society Post-doctoral fellow at Stanford University from 1980-82, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, he became an Associate Professor of Pathology and Cell Biology and Head of the Molecular Diagnostics Lab in Microbiology at Thomas Jefferson University. In 2007, he moved to Temple University, where he is now Professor of Biology. His research has been supported by NIH, industry and foundations for more than 35 years; he has more than 140 publications, and is currently Head of the Professional Science Master’s program in Biotechnology at Temple University. Since 1980, his research interests have encompassed the pathogenesis of chronic hepatitis B infection and development of hepatocellular carcinoma on the cell and molecular levels.
Email: feitelso@temple.edu
PDF HTML